Holen Sie sich die Stockscreener-App
10.72
4.11%
-0.46
Schlusskurs vom Vortag:
$11.18
Offen:
$11.09
24-Stunden-Volumen:
187.44K
Relative Volume:
1.07
Marktkapitalisierung:
$154.61M
Einnahmen:
$6.39M
Nettoeinkommen (Verlust:
$-117.26M
KGV:
-0.8589
EPS:
-12.4807
Netto-Cashflow:
$-79.08M
1W Leistung:
-20.06%
1M Leistung:
-14.85%
6M Leistung:
+52.71%
1J Leistung:
-13.20%
1-Tages-Spanne:
$10.46
$11.28
1-Wochen-Bereich:
$10.46
$13.48
52-Wochen-Spanne:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
Firmenname
Korro Bio Inc
Sektor
Branche
Telefon
617-468-1999
Adresse
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
10.72 | 161.24M | 6.39M | -117.26M | -79.08M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2026-02-17 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2026-01-29 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2026-01-29 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2026-01-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-01-28 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2026-01-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-11-13 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-11-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2025-11-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-11-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-11-13 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-13 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2025-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-16 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2024-08-14 | Eingeleitet | William Blair | Outperform |
| 2024-03-28 | Bestätigt | H.C. Wainwright | Buy |
| 2024-02-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-29 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-10 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | Herabstufung | Cowen | Outperform → Market Perform |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-01-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-22 | Eingeleitet | B. Riley Securities | Buy |
| 2020-07-14 | Eingeleitet | Oppenheimer | Outperform |
| 2020-05-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-10-28 | Eingeleitet | Cowen | Outperform |
| 2019-10-28 | Eingeleitet | Goldman | Buy |
| 2019-10-28 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Korro Bio Inc Aktie (KRRO) Neueste Nachrichten
Korro Bio CEO Ram Aiyar sells $196,672 in company stock - Investing.com
Korro Bio CEO Ram Aiyar sells $196,672 in company stock By Investing.com - Investing.com UK
Korro Bio director sells $39,897 in common stock By Investing.com - Investing.com Australia
Korro Bio director sells $39,897 in common stock - Investing.com
Korro Bio Inc. (KRRO) Faces Selling Pressure as Shares Retreat 3.21%Bear Pennant - The Legal Advocate
KRRO Q1 2026 Earnings: EPS Beat by 10.05% as Biotech Advances PipelineNext Quarter Guidance - The Legal Advocate
Press Release: Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors - Moomoo
Piper Sandler Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates - MSN
Korro Bio, Inc. identifies surge in healthcare burden from ammonia in hepatic encephalopathy - Traders Union
Korro Bio (KRRO) Receives a Buy from H.C. Wainwright - The Globe and Mail
Korro to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Korro Bio Stock Climbs Before Holiday; Bigger Test Still to Come - Bez Kabli
Korro Bio Inc. (KRRO) Surges Nearly 12% as Biotech Momentum BuildsExpert Momentum Signals - Newser
Citigroup initiates coverage of Korro Bio (KRRO) with buy recommendation - MSN
Korro Bio Selects KRRO-111 as RNA Editing Therapy Candidate for Alpha-1 Antitrypsin Deficiency (AATD) with Best-in-Class Preclinical Results 1 - Minichart
Korro Bio, Inc.Common Stock (NQ: KRRO - The Chronicle-Journal
Korro Bio adds AATD treatment candidate to pipeline By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Korro Bio stock price target on financing impact By Investing.com - Investing.com South Africa
Korro Bio nominates new candidate for AATD - BioWorld News
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Korro Bio, Inc. selects KRRO-111 after preclinical success in repairing AAT protein - Traders Union
H.C. Wainwright cuts Korro Bio stock price target on financing impact - Investing.com Nigeria
Korro Bio Advances KRRO-111 for Alpha-1 Deficiency - TipRanks
Korro Bio adds AATD treatment candidate to pipeline - Investing.com
KRRO Initiates Coverage by Citigroup -- Announces Buy Rating - GuruFocus
Citi Initiates Korro Bio(KRRO.US) With Buy Rating, Announces Target Price $21 - Moomoo
Lynx1 Capital Management LP's Korro Bio Inc(KRRO) Holding History - GuruFocus
Citigroup Initiates Korro Bio at Buy With $21 Price Target - marketscreener.com
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Should You Sell Korro Bio (KRRO) After -8.12% Drop? 2026-05-15Stock Picks - Newser
Korro Bio, Inc. advances KRRO-121 RNA editing therapy for hyperammonemia toward clinical stage - Traders Union
New Korro Bio hire gets option for 3,000 shares at $11.20 - Stock Titan
TradingKey - TradingKey
Korro Bio (KRRO) Price Target Decreased by 30.76% to 66.30 - MSN
Korro announces oversubscribed $85 million private placement - MSN
Number of shareholders of Korro Bio, Inc. – NASDAQ:KRRO - TradingView
Korro Bio (NASDAQ:KRRO) Announces Quarterly Earnings Results - MarketBeat
Wave Life Sciences (WVE) Attracts Positive Attention Amid Compet - GuruFocus
JonesTrading Upgrades Korro Bio(KRRO.US) to Buy Rating, Announces Target Price $23 - Moomoo
Jones Trading upgrades Korro Bio stock rating on AATD program potential By Investing.com - Investing.com South Africa
Jones Trading upgrades Korro Bio stock rating on AATD program potential - Investing.com Nigeria
Chardan Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Korro Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Korro Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Finanzdaten der Korro Bio Inc-Aktie (KRRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Korro Bio Inc-Aktie (KRRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FORMELA JEAN FRANCOIS | Director |
May 28 '26 |
Sale |
13.95 |
2,860 |
39,897 |
194,655 |
1.13%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):